TXG 10x Genomics, Inc.
10x Genomics, Inc. (TXG) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.9% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About 10x Genomics, Inc.
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health.
Sector
Healthcare
Industry
Medical Instruments/Supply
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.